高级检索
当前位置: 首页 > 详情页

NF-kappa B-Inducing Kinase Provokes Insulin Resistance in Skeletal Muscle of Obese Mice

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Xinxiang Med Univ, Pharm Coll, Dept Pharmacol, Xinxiang 453003, Henan, Peoples R China [2]Xinxiang key Lab Epigenet Mol Pharmacol, Xinxiang 453003, Henan, Peoples R China [3]Nanjing Med Univ, Sch Basic Med Sci, Dept Pharmacol, 101 Longmian Ave, Nanjing 211166, Jiangsu, Peoples R China [4]Nanjing Med Univ, Affiliated Hosp 1, Dept Rehabil Med, Nanjing 210100, Jiangsu, Peoples R China [5]Guangzhou Univ Chinese Med, Shenzhen Tradit Chinese Med Hosp, Clin Med Coll 4, Dept Pharm, Shenzhen 518033, Guangdong, Peoples R China
出处:
ISSN:

关键词: NF-kappa B-inducing kinase skeletal muscle insulin resistance insulin receptor substrate 1

摘要:
-Skeletal muscle is crucial for preserving glucose homeostasis. Insulin resistance and abnormalities in glucose metabolism result from a range of pathogenic factors attacking skeletal muscle in obese individuals. To relieve insulin resistance and restore glucose homeostasis, blocking the cell signaling pathways induced by those pathogenic factors seems an attractive strategy. It has been discovered that insulin sensitivity in obese people is inversely linked with the activity of NF-?B inducing kinase (NIK) in skeletal muscle. In order to evaluate NIK's pathological consequences, mechanism of action, and therapeutic values, an obese mouse model reproduced by feeding a high-fat diet was treated with a NIK inhibitor, B022. C2C12 myoblasts overexpressing NIK were utilized to assess insulin signaling and glucose uptake. B022 thus prevented high-fat diet-induced NIK activation and insulin desensitization in skeletal muscle. The insulin signaling in C2C12 myoblasts was compromised by the upregulation of NIK brought on by oxidative stress, lipid deposition, inflammation, or adenoviral vector. This inhibition of insulin action is mostly due to an inhibitory serine phosphorylation of IRS1 caused by ERK, JNK, and PKC that were activated by NIK. In summary, NIK integrates signals from several pathogenic factors to impair insulin signaling by igniting a number of IRS1-inhibiting kinases, and it also has significant therapeutic potential for treating insulin resistance.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 2 区 医学
小类 | 3 区 免疫学 3 区 细胞生物学
最新[2025]版:
大类 | 2 区 医学
小类 | 3 区 细胞生物学 3 区 免疫学
JCR分区:
出版当年[2021]版:
Q2 IMMUNOLOGY Q3 CELL BIOLOGY
最新[2023]版:
Q2 CELL BIOLOGY Q2 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Xinxiang Med Univ, Pharm Coll, Dept Pharmacol, Xinxiang 453003, Henan, Peoples R China [2]Xinxiang key Lab Epigenet Mol Pharmacol, Xinxiang 453003, Henan, Peoples R China [3]Nanjing Med Univ, Sch Basic Med Sci, Dept Pharmacol, 101 Longmian Ave, Nanjing 211166, Jiangsu, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Xinxiang Med Univ, Pharm Coll, Dept Pharmacol, Xinxiang 453003, Henan, Peoples R China [2]Xinxiang key Lab Epigenet Mol Pharmacol, Xinxiang 453003, Henan, Peoples R China [3]Nanjing Med Univ, Sch Basic Med Sci, Dept Pharmacol, 101 Longmian Ave, Nanjing 211166, Jiangsu, Peoples R China [4]Nanjing Med Univ, Affiliated Hosp 1, Dept Rehabil Med, Nanjing 210100, Jiangsu, Peoples R China [5]Guangzhou Univ Chinese Med, Shenzhen Tradit Chinese Med Hosp, Clin Med Coll 4, Dept Pharm, Shenzhen 518033, Guangdong, Peoples R China [*1]Department of Pharmacology, Pharmacy College, Xinxiang Medical University, Xinxiang, Henan, 453003, China [*2]Department of Pharmacology, School of Basic Medical Science, Nanjing Medical University, 101 Longmian Avenue, Nanjing, Jiangsu, 211166, China [*3]Department of Rehabilitation Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210100, China [*4]Department of Pharmacy, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518033, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号